Viking Therapeutics Inc’s recent filing unveils that its President & CEO Lian Brian unloaded Company’s shares for reported $1.35 million on Feb 09 ’24. In the deal valued at $29.90 per share,45,000 shares were sold. As a result of this transaction, Lian Brian now holds 2,139,882 shares worth roughly $143.27 million.
Then, Lian Brian sold 269,079 shares, generating $7,230,784 in total proceeds. Upon selling the shares at $26.87, the President & CEO now owns 2,184,882 shares.
Before that, Rouan Sarah Kathryn sold 25,000 shares. Viking Therapeutics Inc shares valued at $701,250 were divested by the Director at a price of $28.05 per share. As a result of the transaction, Rouan Sarah Kathryn now holds 0 shares, worth roughly $0.0.
Oppenheimer reiterated its Viking Therapeutics Inc [VKTX] rating to an Outperform in a research note published on March 26, 2024; the price target was $138. A number of analysts have revised their coverage, including Jefferies’s analysts, who began to cover the stock in early March with a ‘”a Buy”‘ rating. Oppenheimer also remained covering VKTX and reiterated its “an Outperform” recommendation on February 28, 2024.
Price Performance Review of VKTX
On Monday, Viking Therapeutics Inc [NASDAQ:VKTX] saw its stock fall -2.43% to $66.95. Over the last five days, the stock has lost -11.77%. Viking Therapeutics Inc shares have risen nearly 259.75% since the year began. Nevertheless, the stocks have risen 259.56% over the past one year. While a 52-week high of $99.41 was reached on 02/28/24, a 52-week low of $8.28 was recorded on 01/03/24. SMA at 50 days reached $61.14, while 200 days put it at $26.42. A total of 2.13 million shares were traded, compared to the trading of 2.73 million shares in the previous session.
Levels Of Support And Resistance For VKTX Stock
The 24-hour chart illustrates a support level at 65.47, which if violated will result in even more drops to 63.98. On the upside, there is a resistance level at 69.22. A further resistance level may holdings at 71.48. The Relative Strength Index (RSI) on the 14-day chart is 46.19, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -6.79, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 96.93%. Stochastics %K at 5.65% indicates the stock is a buying.
The most recent change occurred on March 28, 2023 when Maxim Group resumed its ‘”a Buy”‘ rating for the stock and retained the price target to $25.
